Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine for Methamphetamine Use Disorder
IRCT2017070234844N1Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of atomoxetine in methamphetamine use disorder (MUD) and Other stimulants dependence syndrome, sponsored by Tehran University of Medical Sciences. Started Aug 2017; status: completed.
02
Drugs
atomoxetine
03
Conditions
methamphetamine use disorder (MUD)Other stimulants dependence syndrome
Beyond the preview
Go deeper on IRCT2017070234844N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2017070234844N1.